Shandong Buchang Pharmaceuticals Co., Ltd.

Equities

603858

CNE100002FV6

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
17.09 CNY +1.06% Intraday chart for Shandong Buchang Pharmaceuticals Co., Ltd. +1.42% +0.47%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023. CI
Buchang Pharma Obtains Green Light to Trial Gastric Cancer Drug Combination MT
Tranche Update on Shandong Buchang Pharmaceuticals Co., Ltd.'s Equity Buyback Plan announced on December 14, 2023. CI
Buchang Pharma’s Drugs Retain National Medical Insurance Coverage MT
Shandong Buchang Pharmaceuticals Co., Ltd. announces an Equity Buyback for CNY 360 million worth of its shares. CI
Shandong Buchang Pharmaceuticals Co., Ltd. authorizes a Buyback Plan. CI
Buchang Pharma's Unit Gets Nod to Test Colorectal Cancer Drug MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Haikou Xinyingyang Investment Partnership Enterprise (Limited Partnership) and Xi Chong agreed to acquire 14% stake in Buchang Health Industry (Zhejiang ) Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd.,Hu Cunchao, Li Hui, and Hu Cunchao for CNY 0. CI
Buchang Pharma Unit Gets Nod to Trial Cancer Treatment MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Selling Expenses of Chinese Listed Pharma Companies About 1.5x Higher Than Net Profits in 2022 MT
Buchang Pharmaceuticals to Set Up Medical Device Subsidiary MT
Buchang Pharma Unit Gets Nod to Make Amendments to Diabetes Drug MT
Buchang Pharmaceuticals to Invest 223 Million Yuan Into Old Factory Upgrade MT
Buchang Pharma's Unit Passes Regulator's Good Manufacturing Practice Evaluation MT
Zhao Yunhua agreed to acquire a 90% stake in Buchang Taoyiyun Health Technology Co., Ltd. from Shandong Buchang Pharmaceuticals Co., Ltd. for CNY 1. CI
Ningbo Buchang Medical Technology Co., Ltd. announced that it expects to receive CNY 3 million in funding from Shandong Buchang Pharmaceuticals Co., Ltd., Shaanxi Deju Bowen Health Technology Co., Ltd. CI
Buchang Pharma Unit Passes Regulatory Inspection MT
Buchang Pharma Unit Gets Nod for Flu Vaccine Trials in China MT
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shandong Buchang Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Changrui Biotechnology Co., Ltd. announced that it has received CNY 64 million in funding from Shandong Buchang Pharmaceuticals Co., Ltd. CI
Buchang Pharma Invests 64 Million Yuan in Local Biotechnology Firm MT
Shandong Buchang Pharmaceuticals Co., Ltd., Pu Xiaoping, Yang Chun and Ma Chongxu agreed to acquire 10.1% stake in Changrui Biotechnology Co., Ltd. from Chengdu Farwits Biotechnology Co., Ltd. for CNY 10.01 million CI
Chart Shandong Buchang Pharmaceuticals Co., Ltd.
More charts
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of Chinese patent medicines. The Company’s main products are compound traditional Chinese medicines, including cerecarton capsules,wenxin granules, as well as danhong injections, among others. Its products are mainly applied to the fields of cardio-cerebrovascular diseases and gynecological diseases. The Company distributes its products within domestic market and to overseas markets, with North China, East China and Central China as its major markets.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 603858 Stock
  4. News Shandong Buchang Pharmaceuticals Co., Ltd.
  5. Buchang Pharmaceuticals Plans to Set Up Headquarters at Shijiazhuang International Biomedical Park